Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look today. Those ae not my trades. But my account likes this. I think I may up the bid though. Is something happening?
First the company needs get their thumb out of their bum and do something that actually justifies folks slapping the ask or raising their bids....lol.
Ask is moving today. Maybe news on the way
Who knows, it's that time of year, so could be someone that had a handful of shares left over from the reverse split and they sold em' to take as a tax loss.
An 8.00 trade. Sorry if I do not get this at all
I am hoping sooner, but maybe they are waiting for Peterson to return from Europe (hopefully with wonderful news) What has happened to all those other exciting ideas? I guess it doesn't matter, as long as we get the new products started.
Well unfortunately it does not look like the new incoming DND President will be Anderson. It now appears his next venture after RAFA is going to be Ostashkov Industrial Inc.(OSKV).
OSKV (fka CACJ) is one of the trio of shells that were obtained by Bailey along with DNDT and JAQC. At one point a couple years ago they were going to roll Best Balms into that one but went with DND for whatever reason instead. Of course the BB deal eventually fell through for DNDT as well.
If the new DND president is not Rosen then I have no clue who it's going to be, whatever the case we should be finding out sooner or later one would think.
I doubt this week but maybe next. New month new president perhaps
Well if there is one thing I have learned from watching these guys and RAFA for the past 2 years is that everything they do takes a loooong arse time to get done. You need to have copious amounts of patience to be invested in any of their ventures and then you have to pray that it pays off...lol.
Things got a little better when Anderson took over RAFA from Peters and Bailey. Up until then communication had been lacking, developments took forever and there was very little attention to detail. Now things happen more efficiently and in a somewhat more timely manor in RAFA. we can only hope that the new president will do the same for DND as Anderson did for RAFA.
I would assume that the bioassaygen.com website will be built by Nexgen Business Solutions, that's who does all of the Ashlin/DNDT sites. It will probably end up being an e-commerce site, so you will be able to purchase merchandise. This design could take a little longer then usual so perhaps that's the holdup.
Looks great. I am through getting impatient. I hope the time passed since acquisition had been used well. I just want a website up. Is that too much to last?
If DND puts half as much effort into selling the Hyamatrix/Bioassaygen products as the Hungarian distributor, GBS, is then I think it will be OK as they are really promoting it heavily and have been for several months now.
http://www.hyamatrix.hu/
http://gbs-europe.com/
https://www.facebook.com/Hyamatrix.hu
https://www.facebook.com/Hyamatrix.hu/photos_stream
I risk sounding like a Ihub poster when I write this, but the only NEWS releases coming from DNDT this year were on a Monday and a Tuesday. I am So sure that is significant since two pieces of news. But I am watching. We will be hearing shortly about the new president, and I expect when that happens we will get an update.
DND has had a somewhat checkered past I suppose but it seems to me like most of the sins were committed when Alexander Lindale, Noumou Diallo and/or Matching Ads controlled the company.
Now it's controlled by Ashlin Global.
Yes Ashlin was still involved in DND back when back when Noumou and Matching Ads were but I don't believe they actually controlled the company per se like they do now.
Whether or not that's a good thing remains to be seen but the acquisition of Bioassaygen was probably the first decent decision the BOD has ever made.
Oh .. One more thing. Whoever you are out there. Go ahead and up the ask again on Monday. .02 sounds great
Seems that way . I really do not get the lack of information. I am positive we will be gettin some sort if news very soon. New president promised website, North American distribution. But oh the waiting is painful. Sill it is a green day. A green week. A green month. :)
It's easier to run a pos with bs than it is a legit company with fundamentals. ( ;
The way I see it, DNDT ran to .06 last time with a much worse share structure, a crap asset in Best Balms and a hell of LOT of baggage, including a bunch of large unsavory shareholders.
This time around it has a better share structure, all of the low life's who held shares sold or were wiped out by the reverse split, and the new asset, Bioassaygen, looks real and promising.
If Ashlin is legit, and the incoming president is even remotely competent, logic says this should easily surpass that .06 if they can ever manage to regain investor confidence again.
The chart may look horrible if you look at the year or more, but we are up about 50% for the month. Not too shabby. With news we could end 2013 in a much more respectable manner. We have made the bounce, where it goes from here is up to management now.
One thing I'll mention is that the current RAFA management have taken the brunt of the heat from investors for the whole JAQC fiasco.
However, the fact is when you look at this timeline the current RAFA mgmt took over at the stage I put in bold and the ball was dropped loooong before that.
JAQC was doomed for failure the moment it was acquired by Ashlin.
Who knows, the good news is that the asset, Bioassaygen, is valued at at least $2M and has been since the beginning when it belonged to JAQC and the public records on OTC Markets prove that.
Lets face it they probably never figured anyone would have paid enough attention to connect the dots on the back history of this asset, however, I did and it all looks legitimate enough to me based on the info that's out there.
Now, this has nothing to do with DNDT but I am not exactly happy that Ashlin came out smelling like a rose in the whole process, despite that fact that they sold and/or gave a defective shell(JAQC)to Bailey.....in fact the ONLY people who were hurt by this were JAQC investors....everyone else got something out of it, DNDT, Bailey, Johnstons, Ashlin, RAFA, etc.
Now IF Ashlin were the ones who put the RAFA shares into the escrow account for JAQC investors then I might be able to cut them some slack, assuming they ever do get distributed that is.....if not then Ashlin looks highly suspect to me.
Thank you Big Brother. The question now is what is DNDT going to do with this new company? Potential is there.. What now?
So lets break down the timeline to see how it unfolded.........
-Ashlin acquires empty JAQC shell from owners of Johnston Trust for an unknown amount
-Bailey acquires JAQC shell from Ashlin for an unknown amount, however, Ashlin also gets to keep at least 3.7M shares of JAQC, maybe more in the transaction
-Bailey acquires Russian asset Quintess, for an unknown amount and from unknown party and puts it into JAQC
-later Bailey sells 30M preferred shares of JAQC to Zdorovie Invest, for 90% of the o/s of Rafarma Pharmaceuticals
-JAQC becomes RAFA after merger of JAQC and APKN(this happened after they realized that JAQC could not become RAFA on it's own due to DTC issues, they needed APKN)
-Ashlin exchanges their JAQC shares for RAFA shares
-RAFA sells off asset Quintess to Ashlin and Ashlin returns 3.7M shares of RAFA
-RAFA returns said 3.7M shares to treasury and reduces their o/s
-Ashlin renames newly acquired asset Quintess..... Adapto-Genic
-Ashlin sells Adapto-Genic to DNDT for 20M restricted shares ($2M dollar value)
-DNDT renames Adapto-Genic....Bioassaygen.
-DNDT issues PR about acquisition.
Some details, here and there, may be incorrect but this is how it appears to me to have all went down based on the info we have available.
Ok, I've been trying to wrap my head around this 'Bioassaygen' acquisition, just to make sense out. It's a confusing story that will probably only make any sense to a small handful of people out there who have been following this for years...lol. Not to mention that the confusion is compounded by the fact that the products have gone by so many different names.......... however, this is what appears to have gone down. We don't know all the facts but I'm trying to piece together what we do know.
- In 2012 the 'Bioassaygen' products, then known as 'Quintess' were an asset of RAFA(fka JAQC), this asset has a value of approximately $2M dollars. You can see it listed under intangible assets on the JAQC Quarterly Report.
https://www.otciq.com/otciq/ajax/showFinancialReportById.pdf?id=87785
- In March, 2013 RAFA(fka JAQC) sold the Quintess line of products, to someone unidentified, for 3.7M shares of RAFA, which were then returned to the treasury.
Yes it it filed and looks good. Yes DNDT issued shares for the new company, but fully restricted shares. (I am not sure exactly what are the restrictions, but I am sure we are safe for now. I am hoping and guessing we get more information either tomorrow or next week. I expect DNDT will update it's website and open a new one for the new company very soon. It is great that they always actually file on time.. now lets see what they do with this new two million dollar asset.
Totally agree. Nite needs to get out of the way today!
Yes it's nice to see some volume pick up but how many shares does that POS NITE have..?? Given the current share structure this should be moving easier IMO. That's been the story with DND the last 2 years though, there is always a shortsighted seller it seems.
I suppose it's possible they could be trying to add some shares for liquidity but it would be better to see them do it at higher prices.
After all the whole point of the reverse split was for them to get the pps up to higher levels for their acquisitions.
Volume starting to pick up. I like this.
I am trying to add a little also. Bid support is my new plan. That way I am getting shares at the best possible price. 3 days till the 15th. I hope they are on time even with Jonathan out of the country.
I've been grabbing a little bit here and there. I had not intended to buy any more Pinks, however, I'm very intrigued by the products and the fact that this was one of Baileys original and only two deals out there, Bioassaygen and Rafarma.
Granted it's not on the same level as Rafarma but much like RAFA it's probably been underestimated and is better then we think. Right now it's a gamble because we still lack many details but it's a gamble worth throwing some lunch money at IMO.
If I like the new incoming president, what their direction for the company is and if they communicate then I will add....but....if it's just another dilutive schmuck then I'll get out and move on.
Only time will tell at this point.
I love the way this is slowly moving up now. Nothing crazy, but just making a nice turn about. Accumulating at these levels might be a very smart move!
Who sold 4000 shares to bring this down today. So silly
Quarterly financials are usually on time, so I am looking for any information I can find this week. Perhaps we will hear about the new president, or distribution in the US of the cosmetic line.
I have a thought about the costs. Having traveled a lot, and having sons who travel a lot, I have noticed that Many things are much more expensive overseas. Even videos and TV's (made in Japan) cost double or more than the same products here. Perhaps we will see a similar comparison when these products are released in the West. Our market for anti-ageing products is huge and if they can get a good some famous middle aged lady to endorse the product, it could really take off. I just hope the company does what it takes and focuses on this one thing. One diamond is worth a lot more than a whole bushel of rocks!
Wow your right the products are very expensive indeed, nothing under $100 US except the eye cream which runs $75 dollars. The actual Bio-Skin goes for around $1375 US dollars.
http://translate.google.com/translate?hl=en&sl=ru&u=http://hyamatrix-ural.ru/content/files/Price.doc&prev=/search%3Fq%3Dhyamatrix%2B%2B3600%26biw%3D1024%26bih%3D614
I totally agree we need IR. Do to some past communications though I am not sure was the president keeping us from hearing much. I think it was the BOD. I hope that the new president and officers will also have shares, as I would think that owning shares should make them want to help build share value. I understand that has not always been the case here, but I makes sense. As the share start building some value, more people will want shares. Maybe with the expected quarter report we will get information on the new president and his or her plans. We did hear of the last presidents plans to keep us informed, but that did not work out too well. I hope the board changes its views and decides it would be great to let out more information. DNDT is at what could be the beginning of something great. I hope all the long term shareholder, and those who my soon be attracted to the new aquisitions will be richly rewarded.
The new president will make or break this company IMO. They will have some nice pieces to work with, for the first time in the companies history, so if they are aggressive and really do want to increase shareholder value then they could potentially do it.
One of the first things I'd like to see them do is to engage an IR firm. I don't usually condone dilution but even if they had to pay for it in restricted shares, in lieu of cash, I'd still go for it. Right now the SS is very tight so the trade off of dilution and stock awareness would be acceptable.
I just spent some time checking out pricing. OK, this is not cheap makeup. The day cream is 3600 rubles - over $110 USD. I imagine if it really is a fountain of youth, it will be worth it.. I wonder how long one bottle lasts.
I can't disagree. Lets get a fresh start! Lets be responsive to shareholders. Maybe a name with a tie to the new aquisition Biotechnologies. Just make sure if there is a name change, that there is no more forward splitting, and we get to keep our shares. So much could be done to make this work, if only...
Next week financials are due. I hope to see more news and maybe a website also.
BTW, Looking at the trades, it sure appears someone is trying very hard to keep the price down with tiny sells. And whenever someone buys at the ask, a quick turnaround is made, so that we cannot seem to really rise. Is it possible that some want to get some more cheap shares before it takes off. It sure feels like a bottom down here.
Hyamatrix/Bioassaygen DD
Keep in mind that all details of this transaction are not 100% fully known, however, this is what we do know...... or at least think we know as of now. I will update this post as more information develops.
On August 27, 2013, DNDT acquired all the inventory, other assets and the exclusive rights to distribute a pharmaceutical line of products in the United States, Canada and Europe from Rafarma Pharmaceuticals(OTC:BB RAFA).
http://www.prweb.com/releases/2013/8/prweb11064769.htm
The products were developed at Orenburg State University by Russian scientists, headed by Ramil Rakhmatullin and have both medicinal and cosmetic uses.
In Russia these products go under the name 'Hyamatrix', however, they have been rebranded by DNDT and will now be sold as 'Bioassaygen' in the US, Canada and Europe. At this point we do not know why the products have been rebranded, only that it has been confirmed by DNDT CEO Jon Peters that Hyamatrix is indeed Bioassaygen.
The inventory of products acquired includes Bioassaygen Gel, Bioassaygen Cosmetic Mask, Bioassaygen Bio-Skin, and Bioassaygen Delivery Gel, all of which will henceforth be manufactured and distributed by DNDT under the “Bioassaygen” name. A contract-manufacturer for the product has already been identified in Europe, and sale and distribution arrangements are currently being made in several European countries.
Their flagship product is the Bioassaygen Bio-Skin, a revolutionary skin replacement bandage used to treat burn victims. This product has won numerous awards and has been covered extensively by news agencies throughout Russia and Europe, including CNN.
Well I really have no idea, I'm just speculating but I hope it's him because he has a very solid and non-dilutive track record with RAF and that's exactly what DND needs.
Everyone else who has ever been involved in DND in the past has given away shares like candy on Halloween, they paid for anything and everything in shares. It's that dilution which ultimately destroyed DND and took all investor confidence along with it.
Right now the company has a new product, clean ss and new president coming onboard. Yes control of the company remains similar with Ashlin now controlling 20M of the 24M o/s and only time will tell if that's a good or bad thing.
I'm willing to give them the benefit of the doubt right now though, I want to see how it goes with the new Pres and what they do with the Hyamatrix products. However, if they start cranking up the ole' share printing press again I'll be first in line to call this a scam.
Updated I box this morning with information about Bioassygen acquisition. I would like to do more and will as soon as a website is created. If board members have any other ideas about updating the webpage, please let me know. I would like to add the video, but I do not know if I should, since it does not mention our products by name, and I would not want to cause confusion to visitors. Input please. I have the feeling that we may be getting more visitors here, once the new products are on the market.
You might be right on. Jonathon Peters told me that he knew from the beginning that this was a one year contract for him. He had been asked to come in and do as much as possible just for one year. It makes sense that they knew already who was going to replace him, but for some reason, they could not do it yet. The timing with Anderson does make this a plausible idea. I know Peters has been working hard, but for some reason he has been blocked from communicating much with us, the shareholders. My hope is that whoever is the new guy, will be able to provide useful and timely information. The next few weeks may prove to be very interesting.
Well he is all over that chart. Lets hope it all comes together, and takes off. DNDT seems to be a sleeping giant here.
The way I see it if the new president is any of those old, large shareholders from New York, that held shares of DND back in '11 and '12, this include Ashlin as far as I'm concerned........ or any of those Utah based Matching Ads clowns or anyone connected to them, then I am less enthusiastic for the future of DND, regardless of how promising the products are.
If it's S.B, Anderson or someone totally new to DND then I'm more confident in it, depending on who the new guy is and what his background is.
All I know is that whoever it is they are going to have their work cut out for em' restoring investor confidence again after that fiasco last time.
I must have missed something, but who is this S.B.? Thanks in advance.
I was actually thinking about the possibility of Anderson stepping in to take the position yesterday. Wouldn't surprise me really. At this point I don't mind even missing out on DNDT and not getting more RAFA. If that pair works out, all I would have to do is look up S.B. on the nevada secretary of state entity search site and find his latest venture, would save countless hours of looking through the otc website searching for that needle in a haystack. Obviously just because S.B. is behind something doesn't mean it will be successful, but we know he is a well connected guy and can make things happen.
Followers
|
72
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8771
|
Created
|
06/16/04
|
Type
|
Free
|
Moderators |
DND Technologies, Inc.
Tel: 1-800-341-8940
Fax: 212-537-9088
954 Lexington Avenue, Suite 505
New York, NY 10021
E-Mail: info@dndtechnologies.com
Website: http://www.dndtechnologies.com/
Press (PR's/News): http://www.dndtechnologies.com/press_release.html
DNDT has already taken a number of strategic and financial positions in research and development activities in both on-going and start-up businesses. In most of these areas, basic research has been completed and DNDT is in the process of obtaining intellectual property rights. Announcements will be made here as soon as project-specific funds and/or strategic partnerships are secured.
As a holding company, DNDT does not have any operations, activities, or other active business. Instead, it owns assets. DNDT anticipates that, as it makes additional acquisitions, these assets will be shares of stock in other corporations, limited liability companies, limited partnerships, private equity funds, hedge funds, publicly traded stocks, bonds, real estate, song rights, brand names, patents, trademarks, copyrights, and other assets that have value.
Recent Acquistion
DND Technologies (www.dndtechnologies.com) has acquired all the inventory, other assets and the exclusive rights to distribute a pharmaceutical line of products in the United States, Canada and Europe. Rebranded by DNDT, the inventory of products includes Bioassaygen Gel, Bioassaygen Cosmetic Mask, Bioassaygen Bio-Skin, and Bioassaygen Delivery Gel, all of which will henceforth be manufactured and distributed by DNDT under the “Bioassaygen”. brand of products. A contract-manufacturer for the product has already been identified in Europe, and sale and distribution arrangements are currently being made in several European countries.
The patented Skin Replacement Bandage and Delivery Gel products are designed to replace natural skin that may have been lost due to burns, frostbite, pressure sores, etc. The Bio-Skin technology is designed to replaces traditional skin grafting by using synthetically-created skin in lieu of natural skin.
Share Structure
Shares Outstanding | 24,402.246 | a/o Jul 15, 2013 |
Authorized Share |
Company Officers/Contacts
President | Jonathan Peters |
Secretary | Janet John |
Transfer Agent(s)
Action Stock Transfer Corporation
2469 E. Fort Union Blvd. #214
Salt Lake City, UT 84121
+1801 274 1088
The Transfer Agent is registered under the Exchange Act
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |